Stocks advance to end first half as G20 in focus
A gauge of global stocks climbed on Friday in advance of a meeting on trade between U.S. President Donald Trump and Chinese President Xi Jinping,...
Oil prices fall, but post weekly gain ahead of G20 talks, OPEC
Oil prices fell on Friday but posted their second straight week of gains ahead of trade talks between the U.S. and Chinese presidents this weekend,...
Hedge fund chief Daniel Loeb opposes United Technologies, Raytheon merger
Billionaire investor Daniel Loeb said on Friday that his hedge fund Third Point LLC will vote against the planned merger of United Technologies Corp and...
Halfway through 2019, tech leads on Wall Street
Technology stocks are Wall Street’s top performers as 2019 hits half-way, with investors betting on lower interest rates, although Apple and chipmakers face turbulence related...
Stocks advance to cap first half as G20 eyed
A gauge of global stocks advanced on Friday ahead of a meeting on trade between U.S. President Donald Trump and Chinese President Xi Jinping, as...
U.S. banks play cat-and-mouse game with Fed on capital returns
An annual stress test of banks introduced by U.S. regulators after the 2007-09 financial crisis to prevent taxpayer bailouts has become a fight over how...
Former Abraaj executive pleads guilty to U.S. charges
A former executive of collapsed Dubai private equity firm Abraaj Capital Ltd on Friday pleaded guilty to U.S. fraud and conspiracy charges, admitting that he...
U.S. court urged to throw out ‘Pharma Bro’ Martin Shkreli’s conviction
A lawyer for former pharmaceutical executive Martin Shkreli on Friday urged a federal appeals court to overturn Shkreli’s criminal conviction for defrauding investors in hedge...
Banks boost Wall Street with G20 in focus
U.S. stocks rose on Friday, as big banks gained after clearing the Federal Reserve’s stress test, while investors kept a watch on the G20 summit...
Sarepta surges after Pfizer gene therapy data raises safety concerns
Shares of Sarepta Therapeutics Inc surged 15% on Friday after some safety concerns were raised in a small, early-stage study of a competing gene therapy...